Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.685 USD | -0.44% | +0.88% | -43.44% |
May. 09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
May. 09 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.44% | 470M | |
+29.43% | 48.16B | |
-1.26% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.10% | 25.59B | |
-22.95% | 18.96B | |
+7.87% | 12.92B | |
+29.14% | 12.03B | |
-1.94% | 11.77B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Transcript : Editas Medicine, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 10